Basisstatistiken
| LEI | 984500444S8BE1EF0179 |
| CIK | 1858685 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Biofrontera Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2026 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 14, 2026 |
Three Months Ended March 31, 2026 Exhibit 99.1 Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update Woburn, MA (May 14, 2026) (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ: BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three months ended March 31, 20 |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40943 Biofronter |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| March 19, 2026 |
DESCRIPTION OF REGISTERED SECURITIES Exhibit 4.1 DESCRIPTION OF REGISTERED SECURITIES The following summary describes the material provisions of our common stock and the warrants that are listed on The Nasdaq Capital Market LLC. Common Stock The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative vot |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2026 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 19, 2026 |
Exhibit 10.33 Supply Agreement This Supply Agreement (“Agreement”) has been made on December 12, 2025 (“Effective Date”) by and between Biofrontera Discovery GmbH, a company with its head office at Hemmelrather Weg 201, D-51377 Leverkusen, Germany (hereinafter called “BIOFRONTERA”) and Midas Pharma GmbH, a company with its head office at Rheinstr. 49, D-55218 Ingelheim, Germany (hereinafter called |
|
| March 19, 2026 |
Conference call will be held today, Thursday, March 19 at 10:00 am ET Exhibit 99.1 Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA (March 19, 2026) (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy ( |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-40943 BIOFRONTERA INC |
|
| March 9, 2026 |
Exhibit 99.1 Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris ● Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle ● 3-hour incubation regimen identified as the most promising protocol for further clinical development ● Acne vulgaris represe |
|
| March 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 9, 2026 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2026 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| February 26, 2026 |
Exhibit 99.1 U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable WOBURN, Mass., February 26, 2026 — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S. Patent Trial and App |
|
| February 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2026 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| February 9, 2026 |
Biofrontera Announces Positive Results in Phase 3 Exhibit 99.1 Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint ● Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz® vs. vehicle gel (p<0.0003) ● Actinic keratosis (AK) is the most common skin condition diagnosed by US dermatologists1 ● If |
|
| January 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2026 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| January 13, 2026 |
Exhibit 99.1 Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth ● Fourth quarter results represent highest quarterly revenue in Company’s history ● Q4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz® ● Full year 2025 revenues also expected to show double-dig |
|
| January 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 31, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| December 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Biofrontera Inc. |
|
| December 5, 2025 |
As filed with the Securities and Exchange Commission on December 5, 2025. As filed with the Securities and Exchange Commission on December 5, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-3765675 (State or other jurisdiction of incorporation or organization) (Primar |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 13, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| November 13, 2025 |
Exhibit 99.1 Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update Conference call will be held today, Thursday, November 13 at 10:00 am ET November 13, 2025 (GLOBE NEWSWIRE) Woburn, MA — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatolog |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40943 Biofro |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| November 7, 2025 |
Biofrontera Inc. announces sale of license to Xepi Exhibit 99.1 Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M ● Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. ● Transaction further bolsters our cash position, which is expected to fund Biofrontera to pro |
|
| November 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| November 7, 2025 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT by and between Pelthos Therapeutics Inc. as Purchaser and Biofrontera Inc. as Seller Dated as of November 6, 2025 TABLE OF CONTENTS Page Article I DEFINITIONS 4 Section 1.1 Certain Defined Terms 4 Section 1.2 Table of Definitions 11 Article II PURCHASE AND SALE; CLOSING 11 Section 2.1 Acquired Assets and Excluded Assets 11 Section 2.2 Assumed Liabilities and Ex |
|
| October 24, 2025 |
Exhibit 10.1 ASSET PURCHASE AGREEMENT by and between BIOFRONTERA AG, BIOFRONTERA PHARMA GMBH, BIOFRONTERA BIOSCIENCE GMBH, as Sellers, and BIOFRONTERA INC. as Buyer, Dated as of October 20, 2025 TABLE OF CONTENTS ARTICLE I DEFINITIONS AND CONSTRUCTION 1 1.1 Definitions. 1 1.2 Interpretation Provisions 11 ARTICLE II PURCHASE AND SALE 11 2.1 Purchase and Sale of Acquired Assets 11 2.2 Excluded Asset |
|
| October 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 20, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| October 24, 2025 |
Exhibit 10.2 EARNOUT AGREEMENT THIS EARNOUT AGREEMENT (this “Agreement”) is made as of October 20, 2025, by and between Biofrontera AG, a German corporation (“AG”), and Biofrontera Inc., a Delaware corporation (“INC”). AG and INC may be referred to, individually, as a “Party” or, collectively, as the “Parties.” WHEREAS, AG and INC have previously negotiated and agreed upon certain transaction term |
|
| October 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 23, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| October 23, 2025 |
Biofrontera Inc. Closes Purchase of All Ameluz Exhibit 99.1 Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG ● Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG. ● New earnout structure reduces payment rate to 12%–15% of U.S. net sales from 25%–35%. ● Closing releases final $2.5 million of $11 m |
|
| September 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 15, 2025 |
Biofrontera Inc. · 120 Presidential Way, Suite 330 · Woburn, MA 01801 · USA Biofrontera Inc. · 120 Presidential Way, Suite 330 · Woburn, MA 01801 · USA VIA EDGAR August 15, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Biofrontera Inc. Registration Statement on Form S-1 (File No. 333-288717) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 u |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40943 Biofrontera |
|
| August 13, 2025 |
As filed with the Securities and Exchange Commission on August 13, 2025. As filed with the Securities and Exchange Commission on August 13, 2025. Registration No. 333-288717 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-3765675 (State or other jurisdiction of incorporation |
|
| August 13, 2025 |
Exhibit 3.3 |
|
| August 13, 2025 |
Exhibit 99.1 Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2 |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 11, 2025 |
Employment Agreement dated July 18, 2025 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made as of July 18, 2025 (the “Effective Date”), by and between Biofrontera, Inc, a Delaware corporation (the “Company”) having its principal office at 120 Presidential Way, Suite 330, Woburn, MA 01801 and George P. Jones, an individual residing in Green Brook, New Jersey (the “Executive”). BACKGROUND INFORMATION The |
|
| August 11, 2025 |
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer Exhibit 99.1 Biofrontera Inc. Appoints George Jones as Chief Commercial Officer Woburn, MA, August 11, 2025 – Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as Chief Commercial Officer (CCO), starting August 25, 2025. In this role, Mr. Jones |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| July 16, 2025 |
Exhibit 10.2 June 30, 2025 Term Sheet among Biofrontera AG, Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH Hemmelrather Weg 201 51377 Leverkusen, Germany (“Sellers Group” or “Sellers”) and Biofrontera Inc. 120 Presidential Way Woburn, MA 01801 USA (“Buyer”) Buyer, Biofrontera AG, Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH each a “Party” and together the “Parties” to Acquire U |
|
| July 16, 2025 |
As filed with the Securities and Exchange Commission on July 16, 2025. As filed with the Securities and Exchange Commission on July 16, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-3765675 (State or other jurisdiction of incorporation or organization) (Primary S |
|
| July 16, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Biofrontera, Inc. |
|
| July 16, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) |
|
| July 1, 2025 |
Exhibit 3.1 Execution Version BIOFRONTERA INC. Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock Pursuant To Section 151 of the Delaware General Corporation Law BIOFRONTERA INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 1, 2025 |
Exhibit 3.2 Execution Version BIOFRONTERA INC. Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock Pursuant To Section 151 of the Delaware General Corporation Law BIOFRONTERA INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify |
|
| July 1, 2025 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 27, 2025, by and among Biofrontera Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and |
|
| June 30, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 30, 2025 |
Exhibit 99.1 Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment ● Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG. ● Under their new agreement, the effective royalty rate paid by Biofrontera |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 11, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 11, 2025 |
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG Exhibit 99.1 BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG WOBURN, Mass. (June 11, 2025) – Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), confirms a disclosure by the Management Board of Biofrontera AG on June 10, 2025, according to which the two companies are |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 3, 2025 |
Exhibit 99.1 SUPPLEMENT DATED JUNE 3, 2025 TO THE PROXY STATEMENT FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS OF BIOFRONTERA INC. To Be Held on June 12, 2025 Explanatory Note On April 30, 2025, Biofrontera Inc. (the “Company”) filed a Proxy Statement (the “Proxy Statement”) with the Securities and Exchange Commission in connection with the Company’s 2025 Annual Meeting of Stockholders to be held J |
|
| May 23, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 15, 2025 |
Exhibit 99.1 Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 May 15, 2025 / Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40943 Biofronter |
|
| May 15, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 14, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| April 18, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 18, 2025 |
Letter from Marcum LLP, dated April 17, 2025, addressed to the Securities and Exchange Commission Exhibit 16.1 |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| March 21, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2025 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 21, 2025 |
BIOFRONTERA INC. CONSOLIDATED BALANCE SHEETS (In thousands, except par value and share amounts) Exhibit 99.1 Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 / Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the |
|
| March 20, 2025 |
Exhibit 4.1 DESCRIPTION OF REGISTERED SECURITIES The following summary describes the material provisions of our common stock and the warrants that are listed on The Nasdaq Capital Market LLC. Common Stock The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative vot |
|
| March 20, 2025 |
Exhibit 19.1 BIOFRONTERA INC INSIDER TRADING POLICY This Insider Trading Policy (the “Policy”) describes the standards of Biofrontera, Inc and its subsidiaries (the “Company”) on trading, and causing the trading of, the Company’s securities or securities of certain other publicly traded companies by directors, officers, and employees of the Company while in possession of confidential information ( |
|
| March 20, 2025 |
Exhibit 21.1 List of Subsidiaries of the Company Discovery GmbH Germany Biofrontera Life Science LLC Texas |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-40943 BIOFRONTERA INC |
|
| February 12, 2025 |
EX-99.A BD-DIR-RESOL 2 rosalindbfriexa.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of BIOFRONTERA INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Dire |
|
| January 24, 2025 |
Biofrontera Inc. 120 Presidential Way, Suite 330 Woburn, MA 01801 USA Biofrontera Inc. 120 Presidential Way, Suite 330 Woburn, MA 01801 USA VIA EDGAR January 24, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Biofrontera Inc. Registration Statement on Form S-1 (File No. 333-284371) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 under |
|
| January 22, 2025 |
January 22, 2025 Prof. Hermann Luebbert, Ph.D. Chairman and Chief Executive Officer Biofrontera Inc. 120 Presidential Way, Suite 330 Woburn, MA 01801 Re: Biofrontera Inc. Registration Statement on Form S-1 Filed January 17, 2025 File No. 333-284371 Dear Prof. Hermann Luebbert Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rul |
|
| January 17, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Biofrontera Inc. |
|
| January 17, 2025 |
As filed with the Securities and Exchange Commission on January 17, 2025. As filed with the Securities and Exchange Commission on January 17, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-3765675 (State or other jurisdiction of incorporation or organization) (Primar |
|
| December 20, 2024 |
Exhibit 99.4 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned each hereby constitutes and appoints Philipp Wiedmann, Dr. Martin Flick and Alexander Link, and each of them separately and singly, his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be |
|
| December 20, 2024 |
Schedule 1 Members of Management of the Reporting Entities The members of the supervisory board of BFAG are Alexander Link (chairman), Helge Lubenow (deputy Chairman), Hansjörg Plaggemars, Tobias Reich, Karlheinz Schmelig and Heikki Lanckriet. |
|
| December 20, 2024 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 21, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| November 27, 2024 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 21, 2024, by and among Biofrontera Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company |
|
| November 27, 2024 |
Exhibit 10.2 Execution Version SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of November 21, 2024 (this “Agreement”), is among Biofrontera, Inc., a Delaware corporation (the “Company”), and each Subsidiary of the Company which shall become a party to this Agreement by execution and delivery of the form annexed hereto as Annex A and the Subsidiary Guaranty annexed thereto (each such Subsidia |
|
| November 27, 2024 |
Exhibit 4.1 Execution Version FORM OF SENIOR SECURED CONVERTIBLE NOTE NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES COMMISSION OF ANY STATE OR UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SE |
|
| November 22, 2024 |
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note Exhibit 99.1 Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note WOBURN, Mass. (November 22, 2024) – Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the completion of a private placement of a $4.2 million senior secured convertible no |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| November 14, 2024 |
BFRI / Biofrontera Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-bfri093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biofrontera Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 09077D209 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 14, 2024 |
BFRI / Biofrontera Inc. / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biofrontera Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 09077D209 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| November 14, 2024 |
Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is made effective as of November 12, 2024 by and between Biofrontera, Inc, a Delaware corporation (the “Company”) having its registered office at 120 Presidential Way, Suite 330, Woburn, MA 01801 and Hermann Luebbert (the “Executive”) of Hoehenstrasse 59, 51381 Leverkusen, |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40943 Biofro |
|
| November 13, 2024 |
BFRI / Biofrontera Inc. / Saad Nabil - AMENDMENT NO. 1 TO SC13G Passive Investment SC 13G/A 1 sc13ga.htm AMENDMENT NO. 1 TO SC13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biofrontera Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 09077D209 (CUSIP Number) October 31, 2024 (Date of Event which Requires Filing of this Statement) Check the app |
|
| November 13, 2024 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) BIOFRONTERA INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Issued Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per sha |
|
| November 13, 2024 |
Exhibit 99.1 Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update ● Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton. ● Total revenues for the first 9 months were $24.8 million, an increase of $1.3 million, or |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 13, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| November 13, 2024 |
As filed with the Securities and Exchange Commission on __________________ As filed with the Securities and Exchange Commission on Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (Exact name of registrant as specified in its charter) Delaware 47-3765675 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification N |
|
| November 6, 2024 |
BFRI / Biofrontera Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindbfri13ga3nov2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 3) Under the Securities Exchange Act of 1934 BIOFRONTERA INC. (Name of Issuer) Common Shares (Title of Class of Securities) 09077D209 (CUSIP Number) October 31, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 6, 2024 |
EX-99.A BD-DIR-RESOL 2 rosalindbfriexa.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of BIOFRONTERA INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Dire |
|
| November 1, 2024 |
BFRI / Biofrontera Inc. / Bigger Capital, LLC Passive Investment SC 13G/A 1 sc13ga110022bfri11012024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Biofrontera Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 090 |
|
| October 31, 2024 |
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz Exhibit 99.1 Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) ● First Phase 3 PDT study in patients with sBCC in the United States. ● Primary and secondary endpoints all highly statistically significant p<0.0001 ● Correlates to data seen in Europe where sBCC is already inc |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| October 23, 2024 |
BFRI / Biofrontera Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindbfri13ga2sep2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2) Under the Securities Exchange Act of 1934 BIOFRONTERA INC. (Name of Issuer) Common Shares (Title of Class of Securities) 09077D209 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| October 23, 2024 |
EX-99.A BD-DIR-RESOL 2 rosalindbfriexa.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of BIOFRONTERA INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Dire |
|
| October 7, 2024 |
Exhibit 99.1 FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment ● Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz®-PDT using the BF-RhodoLED or the RhodoLED XL lamp ● Supplemental New Drug Application (sNDA) supported by two Phase 1 safety studies ● AK is the second most c |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 7, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 12, 2024 |
BFRI / Biofrontera Inc. / Saad Nabil - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biofrontera Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 09077D209 (CUSIP Number) August 15, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40943 Biofrontera |
|
| August 14, 2024 |
Exhibit 99.1 Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update Woburn, MA / August 14, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and six months ended June 30, 2024 and provided a business update. Highligh |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 24, 2024 |
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp Exhibit 99.1 Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp ● The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalp ● Biofrontera launched the commercial distribution of the RhodoLED |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 24, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 14, 2024 |
Exhibit 10.1 Biofrontera Inc Amended and Restated 2021 OMNIBUS INCENTIVE PLAN 1. Purpose The purpose of the Plan is to provide a means through which the Company and its Affiliates may attract able persons to enter and remain in the employ of the Company and its Affiliates and to provide a means whereby employees, directors and consultants of the Company and its Affiliates can acquire and maintain |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 29, 2024 |
BFRI / Biofrontera Inc. / Rosalind Advisors, Inc. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 BIOFRONTERA INC. (Name of Issuer) Common Shares (Title of Class of Securities) 09077D209 (CUSIP Number) May 13, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| May 29, 2024 |
Schedule 13G Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of BIOFRONTERA INC. |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 15, 2024 |
Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is made as of May 10, 2024, by and between Biofrontera, Inc, a Delaware corporation (the “Company”) having its registered office at 120 Presidential Way, Suite 330, Woburn, MA 01801 and E. Fred Leffler, III (the “Executive”). BACKGROUND INFORMATION WHEREAS, the Company entered in |
|
| May 15, 2024 |
Exhibit 10.1 Amendment NO. 2 to SeTTLEMENT Agreement This amendment number 2 (this “Amendment”), dated as of May 6, 2024 (the “Effective Date”) and entered into by and among Biofrontera Inc. (“BFRI”), Hermann Luebbert, John J. Borer, Beth J. Hoffman, Kevin D. Weber (collectively, the “BFRI Parties”) and Biofrontera AG (each, a “Party” and collectively, the “Parties”), hereby amends that certain Se |
|
| May 15, 2024 |
Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is made effective as of May 10, 2024 by and between Biofrontera, Inc, a Delaware corporation (the “Company”) having its registered office at 120 Presidential Way, Suite 330, Woburn, MA 01801 and Hermann Luebbert (the “Executive”) of Hoehenstrasse 59, 51381 Leverkusen, Germany. BA |
|
| May 15, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 15, 2024 |
Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update Exhibit 99.1 Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update Conference call begins at 10:00 a.m. Eastern time on Thursday, May16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (Nasdaq:BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for t |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40943 Biofronter |
|
| May 8, 2024 |
United States securities and exchange commission logo May 8, 2024 Hermann Luebbert, Ph. |
|
| May 8, 2024 |
Biofrontera Inc. · 120 Presidential Way, Suite 330 · Woburn, MA 01801 · USA Biofrontera Inc. · 120 Presidential Way, Suite 330 · Woburn, MA 01801 · USA VIA EDGAR May 8, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Biofrontera Inc. Registration Statement on Form S-1 (File No. 333-279090) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 under |
|
| May 7, 2024 |
BFRI / Biofrontera Inc. / Hewlett Fund LP - SCHEDULE 13G Passive Investment SC 13G 1 ea0205428-13ghewlettbio.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) BIOFRONTERA INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 09077D209 (CUSIP Number) February 22, 2024 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) C |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 3, 2024 |
As filed with the Securities and Exchange Commission on May 2, 2024. As filed with the Securities and Exchange Commission on May 2, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-3765675 (State or other jurisdiction of incorporation or organization) (Primary Sta |
|
| May 3, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Biofrontera Inc. |
|
| May 3, 2024 |
Exhibit 99.1 Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants WOBURN, MA / ACCESSWIRE / May 3, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that the Board of Directors has met and certified that two criteria descr |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 30, 2024 |
Exhibit 3.1 CERTIFICATE OF SECOND AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OF BIOFRONTERA INC. Biofrontera Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST. The Amended and Restated Certificate of Incorporation of the Corporation, as amende |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 24, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 22, 2024 |
Biofrontera Inc. · 120 Presidential Way, Suite 330 · Woburn, MA 01801 · USA Biofrontera Inc. · 120 Presidential Way, Suite 330 · Woburn, MA 01801 · USA VIA EDGAR April 22, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Biofrontera Inc. Registration Statement on Form S-1 (File No. 333-277811) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 un |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 26, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) |
|
| March 26, 2024 |
Exhibit 99.1 Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that its 2024 Annual Meeting of Stockholders will be held on June 12, 2024 and that the close |
|
| March 26, 2024 |
Other Events, Shareholder Director Nominations, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 26, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Biofrontera Inc. |
|
| March 20, 2024 |
As filed with the Securities and Exchange Commission on March 19, 2024. As filed with the Securities and Exchange Commission on March 19, 2024. Registration No. 333-277811 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-3765675 (State or other jurisdiction of incorporation o |
|
| March 20, 2024 |
BFRI / Biofrontera Inc. / LYTTON LAURENCE W Passive Investment b UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biofrontera Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 09077D209 (CUSIP Number) February 20, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| March 20, 2024 |
BFRI / Biofrontera Inc. / Rosalind Advisors, Inc. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BIOFRONTERA INC. (Name of Issuer) Common Shares (Title of Class of Securities) 09077D209 (CUSIP Number) March 20, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| March 20, 2024 |
Schedule 13G Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of BIOFRONTERA INC. |
|
| March 20, 2024 |
EX-99.A BD-DIR-RESOL 2 rosalindbfriexa.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of BIOFRONTERA INC. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Dire |
|
| March 20, 2024 |
BFRI / Biofrontera Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Biofrontera, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 09077D209 (CUSIP Number) February 20, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| March 20, 2024 |
BFRI / Biofrontera Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G 1 rosalindbfri13gmar202.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BIOFRONTERA INC. (Name of Issuer) Common Shares (Title of Class of Securities) 09077D209 (CUSIP Number) March 20, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| March 18, 2024 |
United States securities and exchange commission logo March 18, 2024 Dr. Hermann Luebbert Chairman and Chief Executive Officer Biofrontera Inc. 120 Presidential Way, Suite 330 Woburn, MA 01801 Re: Biofrontera Inc. Registration Statement on Form S-1 Filed March 11, 2024 File No. 333-277811 Dear Dr. Hermann Luebbert: Our initial review of your registration statement indicates that it fails in numero |
|
| March 15, 2024 |
Exhibit 10.35 BUSINESS LOAN AND SECURITY AGREEMENT THIS BUSINESS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “Agreement”) dated as of December 21, 2023 (the “Effective Date”) among Cedar Advance, LLC as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), and Ceda |
|
| March 15, 2024 |
List of Subsidiaries of the Company Exhibit 21.1 List of Subsidiaries of the Company Bio-Fri GmbH Germany |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-40943 BIOFRONTERA INC |
|
| March 15, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 15, 2024 |
Exhibit 99.1 Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024 March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and tw |
|
| March 15, 2024 |
Compensation Clawback Policy, as approved by the Board of Directors on November 29, 2023 Exhibit 97 Compensation Clawback Policy 1. Purpose and Scope. Biofrontera Inc. (the “Company”) has adopted this Compensation Clawback Policy (the “Policy”) to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (“Dodd-Frank”), as codified by Section 10D of the Securities Exchange Act of 1934 (the “Exchange Act”), which requires the recovery of certain f |
|
| March 15, 2024 |
Exhibit 4.1 DESCRIPTION OF REGISTERED SECURITIES (For information about securities we issued subsequent to December 31, 2023, please refer to our Current Report on Form 8-K filed with the Securities and Exchange Commission on February 23, 2024) The following summary describes the material provisions of our common stock and the warrants that are listed on The Nasdaq Capital Market LLC. Common Stock |
|
| March 15, 2024 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 15, 2024 with respect to the shares of Common Stock of Biofrontera Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Secu |
|
| March 15, 2024 |
BFRI / Biofrontera Inc. / Bigger Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Biofrontera Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 09077D209 (CUSIP Number) February 19, 2024 ( |
|
| March 15, 2024 |
Exhibit 10.34 AMENDED AND RESTATED BUSINESS LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED BUSINESS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “Agreement”) dated as of December 21, 2023 (the “Effective Date”) among Agile Capital Funding, LLC as collateral agent (in such capacity, together with its successors and assig |
|
| March 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Biofrontera Inc. |
|
| March 11, 2024 |
As filed with the Securities and Exchange Commission on March 8, 2024. As filed with the Securities and Exchange Commission on March 8, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-3765675 (State or other jurisdiction of incorporation or organization) (Primary S |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 19, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| February 23, 2024 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT February 19, 2024 Roth Capital Partners, LLC 57 W 57th Street, 16th Floor New York, NY 10019 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Biofrontera Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of 6,586.373 shares (the “Shares”) of the Company’s Series B-1 Conver |
|
| February 23, 2024 |
Exhibit 99.1 Biofrontera Inc. Announces Closing of Private Placement of Up To $16.0 Million priced at market per Nasdaq rules Ø Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Ø Funding and recent restructuring of supply agreement allow Biofrontera Inc. to assume |
|
| February 23, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 19, 2024, by and among Biofrontera Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each Purchaser |
|
| February 23, 2024 |
Exhibit 4.1 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON CONVERSION OR EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES AND THE SECURITIES ISSUABLE UPON CONVERSION OR EXERCISE OF THESE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE |
|
| February 23, 2024 |
Exhibit 3.1 BIOFRONTERA, INC. Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock Pursuant To Section 151 of the Delaware General Corporation Law BIOFRONTERA INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in accorda |
|
| February 20, 2024 |
Exhibit 10.2 Release of Claims This Release of Claims (the “Agreement”) dated February 13, 2024 by and between Biofrontera Pharma GmbH, a German corporation with its principal offices at Hemmelrather Weg 201, 51377 Leverkusen, Germany (“PHARMA”), Biofrontera Bioscience GmbH, a German corporation with its principal offices at Hemmelrather Weg 201, 51377 Leverkusen, Germany (“BIOSCIENCE”) (collectiv |
|
| February 20, 2024 |
Exhibit 10.1 Second Amended and Restated License and Supply Agreement This Second Amended and Restated License and Supply Agreement (the “Amendment”) is made effective as of February 13, 2024, by and between Biofrontera Pharma GmbH, a German corporation with its principal offices at Hemmelrather Weg 201, 51377 Leverkusen, Germany (“PHARMA”), Biofrontera Bioscience GmbH, a German corporation with i |
|
| February 20, 2024 |
Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Exhibit 99.2 Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Ø Company secures financing of $8 million with an additional $8 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Ø Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and to support further commercial |
|
| February 20, 2024 |
Biofrontera Inc. · 120 Presidential Way, Suite 330 · Woburn, MA 01801 · USA Biofrontera Inc. · 120 Presidential Way, Suite 330 · Woburn, MA 01801 · USA VIA EDGAR February 20, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: Biofrontera Inc. Request for Withdrawal of Registration Statement on Form S-1 File No. 333-276535 Dear Mr. Edwards: Pursuant to Rule 4 |
|
| February 20, 2024 |
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG Exhibit 99.1 Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG Ø Ameluz® transfer price to Biofrontera AG reduced significantly Ø Control of all US clinical trials of Ameluz transfers to Biofrontera Inc. on June 1 WOBURN, MA / ACCESSWIRE / February 20, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| February 14, 2024 |
US09077D2099 / BIOFRONTERA INC / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| February 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| February 5, 2024 |
Exhibit 99.1 Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz® to Permit Up to Three Tubes per Use FDA has set a target action date of October 4, 2024 sNDA supported by two Phase 1 safety studies1 Aims at actinic keratosis (AK) field treatment with up to 3 tubes An estimated 13 million treatments given each year for AK in the US2 WOBURN, Mass. (February 5, 2024 |
|
| February 2, 2024 |
Exhibit 10.1 Amended and Restated Addendum to Amended and Restated License and Supply Agreement This Amended and Restated Addendum to Amended and Restated License and Supply Agreement (the “Amended Addendum”) is made effective as of January 26, 2024, by and between Biofrontera AG (“AG”), Biofrontera Pharma GmbH (“PHARMA”), and Biofrontera Bioscience GmbH (“BIOSCIENCE”), each a German corporation/c |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| January 29, 2024 |
Form of Securities Purchase Agreement Exhibit 10.38 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2024, between Biofrontera Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (including each purchaser’s successors and assigns, individually, a “Purchaser”, in the aggregate, the “Purchasers”). Capitalized terms used and not ot |
|
| January 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Biofrontera, Inc. |
|
| January 29, 2024 |
Exhibit 4.15 BIOFRONTERA INC. PRE-FUNDED COMMON STOCK PURCHASE WARRANT Warrant Shares: [] Initial Exercise Date: [], 2024 Issue Date: [], 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, []. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| January 29, 2024 |
Exhibit 4.14 BIOFRONTERA INC. COMMON STOCK PURCHASE WARRANT Warrant Shares: [] Initial Exercise Date: [], 2024 Issue Date: [], 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, []. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h |
|
| January 29, 2024 |
Form of Placement Agent Agreement Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [], 2024 Roth Capital Partners, LLC 57 W 57th Street, 16th Floor New York, NY 10019 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Biofrontera Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $[] of registered securities of the Company, consisting of [] shares (the “S |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024. As filed with the Securities and Exchange Commission on January 29, 2024. Registration No. 333-276535 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-3765675 (State or other jurisdiction of incorporation |
|
| January 25, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 19, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| January 17, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Biofrontera, Inc. |
|
| January 17, 2024 |
As filed with the Securities and Exchange Commission on January 16, 2024. As filed with the Securities and Exchange Commission on January 16, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-3765675 (State or other jurisdiction of incorporation or organization) (Primar |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2024 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| January 11, 2024 |
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023 Exhibit 99.1 Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023 January 11, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenues for the three and twelve months ended December 31, 2023. Biofrontera achieved 2023 revenue of approximat |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporati |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| January 3, 2024 |
Exhibit 10.1 CONFIDENTIAL SETTLEMENT AGREEMENT AND MUTUAL RELEASE This Confidential Settlement Agreement and Mutual Release (the “Settlement Agreement”) is entered into effective as of December 22, 2023 (the “Effective Date”) by and among Biofrontera Inc. (“B- Inc.”), a Delaware corporation (on behalf of itself and as successor to Biofrontera Newderm LLC, a Delaware limited liability company (“B-N |
|
| December 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| December 15, 2023 |
Exhibit 10.1 Addendum to Amended and Restated License and Supply Agreement This Addendum to Amended and Restated License and Supply Agreement (the “Addendum”) is made effective as of December 5, 2023, by and between Biofrontera AG (“AG”), Biofrontera Pharma GmbH (“PHARMA”), and Biofrontera Bioscience GmbH (“BIOSCIENCE”), each a German corporation/company with its principal offices at Hemmelrather |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 12, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| November 29, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| November 9, 2023 |
Exhibit 99.1 Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update Conference call begins at 10:00 a.m. Eastern time on Friday, November 10, 2023 WOBURN, Mass. (November 9, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for th |
|
| November 9, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40943 Biofro |
|
| November 2, 2023 |
Exhibit 99.1 Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules October 31, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, entered into a securities purchase agreement with a certain institutional investor, pursuant to which th |
|
| November 2, 2023 |
Exhibit 10.3 AMENDMENT TO COMMON STOCK PURCHASE WARRANTS October 30, 2023 This Amendment (the “Amendment”), dated October 30, 2023 and effective as of November 2, 2023 (the “Effective Date”), to certain common stock warrants issued by Biofrontera Inc., a Delaware corporation (the “Company”), and set forth on Schedule 1 hereto, to purchase the Company’s common stock, par value $0.0001 (“Common Stoc |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| November 2, 2023 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 30, 2023, between Biofrontera Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (including each purchaser’s successors and assigns, individually, a “Purchaser”, in the aggregate, the “Purchasers”). Capitali |
|
| November 2, 2023 |
Exhibit 10.2 Execution Version PLACEMENT AGENCY AGREEMENT October 30, 2023 Roth Capital Partners, LLC 57 W 57th Street, 16th Floor New York, NY 10019 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Biofrontera Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $4,506,700 of registered securities of the Compan |
|
| November 2, 2023 |
Exhibit 4.2 Execution Version BIOFRONTERA INC. PRE-FUNDED COMMON STOCK PURCHASE WARRANT Warrant Shares: [] Initial Exercise Date: November 2, 2023 Issue Date: November 2, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se |
|
| November 2, 2023 |
Exhibit 4.1 Execution Version BIOFRONTERA INC. COMMON STOCK PURCHASE WARRANT Warrant Shares: [] Initial Exercise Date: November 2, 2023 Issue Date: November 2, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, []. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a |
|
| November 1, 2023 |
PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-274871 150,000 Shares of Common Stock 1,055,00 Pre-Funded Warrants to Purchase Up to 1,055,000 Shares of Common Stock 1,205,000 Warrants to Purchase Up to 1,807,500 Shares of Common Stock 1,807,500 Shares of Common Stock Underlying the Warrants 1,055,000 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering on a b |
|
| October 27, 2023 |
Form of Securities Purchase Agreement Exhibit 10.33 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October [], 2023, between Biofrontera Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (including each purchaser’s successors and assigns, individually, a “Purchaser”, in the aggregate, the “Purchasers”). Recitals Subject to the t |
|
| October 27, 2023 |
Form of Placement Agent Agreement Exhibit 1.1 PLACEMENT AGENCY AGREEMENT [●], 2023 Roth Capital Partners, LLC 57 W 57th Street, 16th Floor New York, NY 10019 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Biofrontera Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $[●] of registered securities of the Company, consisting of [●] shares (the |
|
| October 27, 2023 |
As filed with the Securities and Exchange Commission on October 26, 2023. As filed with the Securities and Exchange Commission on October 26, 2023. Registration No. 333-274871 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-3765675 (State or other jurisdiction of incorporation |
|
| October 27, 2023 |
Biofrontera Inc. · 120 Presidential Way, Suite 330 · Woburn, MA 01801 · USA Biofrontera Inc. · 120 Presidential Way, Suite 330 · Woburn, MA 01801 · USA VIA EDGAR October 27, 2023 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Biofrontera Inc. Registration Statement on Form S-1 (File No. 333-274871) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 |
|
| October 27, 2023 |
Exhibit 4.13 BIOFRONTERA INC. PRE-FUNDED COMMON STOCK PURCHASE WARRANT Warrant Shares: [ ] Initial Exercise Date: October [●], 2023 Issue Date: October [●], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any t |
|
| October 27, 2023 |
Exhibit 4.12 BIOFRONTERA INC. COMMON STOCK PURCHASE WARRANT Warrant Shares: [ ] Initial Exercise Date: October [●], 2023 CUSIP: 09077D 126 Issue Date: October [●], 2023 ISIN: US09077D1265 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions herei |
|
| October 27, 2023 |
Form of Warrant Agent Agreement Exhibit 4.14 WARRANT AGENT AGREEMENT This Warrant Agent Agreement (“Warrant Agreement”) is made as of October [], 2023, by and among Biofrontera Inc., a Delaware corporation, with offices at 120 Presidential Way, Suite 330, Woburn, Massachusetts 01801 (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A. a federally c |
|
| October 16, 2023 |
As filed with the Securities and Exchange Commission on October 13, 2023. As filed with the Securities and Exchange Commission on October 13, 2023. Registration No. 333-274871 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-3765675 (State or other jurisdiction of incorporation |
|
| October 13, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 12, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| October 13, 2023 |
VIA EDGAR AND EMAIL October 13, 2023 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| October 13, 2023 |
Exhibit 10.1 Amendment NO. 1 to SeTTLEMENT Agreement This amendment number 1 (this “Amendment”), dated as of October 12, 2023 (the “Effective Date”) and entered into by and among Biofrontera Inc. (“BFRI”), Hermann Luebbert, John J. Borer, Beth J. Hoffman, Kevin D. Weber (collectively, the “BFRI Parties”) and Biofrontera AG (each, a “Party” and collectively, the “Parties”), hereby amends that certa |
|
| October 11, 2023 |
United States securities and exchange commission logo October 11, 2023 Hermann Luebbert Chief Executive Officer Biofrontera Inc. |
|
| October 10, 2023 |
Exhibit 99.1 Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz® Patent Application Filed with Potential to Extend Ameluz® Protection to 2043 WOBURN, Mass. (October 10, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that its licensor Biofrontera B |
|
| October 10, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File |
|
| October 5, 2023 |
As filed with the Securities and Exchange Commission on October 4, 2023. As filed with the Securities and Exchange Commission on October 4, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOFRONTERA INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-3765675 (State or other jurisdiction of incorporation or organization) (Primary |
|
| October 5, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Biofrontera, Inc. |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 4, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File N |
|
| October 4, 2023 |
Exhibit 99.1 Biofrontera Inc. Announces Preliminary Third Quarter Revenues Revenues Increased 101% to 108% Over the Prior-Year Quarter Affirms Guidance for Full-Year Revenue Growth of at Least 25% over 2022 WOBURN, Mass. (October 4, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, t |
|
| October 3, 2023 |
Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS Page Audited Financial Statements as of and for the Years Ended December 31, 2022 and 2021 Report of Independent Registered Public Accounting Firm (PCAOB ID No. 688) F-2 Consolidated Balance Sheets as of December 31, 2022 and 2021 F-3 Consolidated Statements of Operations for the years ended December 31, 2022 and 2021 F-4 Consolidated Statements of Stockh |
|
| October 3, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 3, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File N |
|
| October 3, 2023 |
For the Year Ended December 31, Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations The following section contains statements that are not statements of historical fact and are forward-looking statements within the meaning of the federal securities laws. These statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, |
|
| August 11, 2023 |
Exhibit 99.1 Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update Conference call begins at 8:30 a.m. Eastern time today WOBURN, Mass. (August 11, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and six months e |
|
| August 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40943 Biofrontera |
|
| August 11, 2023 |
Exhibit 10.1 |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 13, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 13, 2023 |
Exhibit 99.1 Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31% Management Reaffirms Full-Year 2023 Revenue Growth of at least 25% over Prior Year WOBURN, Mass. (July 13, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced preliminary unaud |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 12, 2023 |
Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors Exhibit 99.1 Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors WOBURN, Mass. (July 12, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the appointment of Heikki Lanckriet, Ph.D. to its Board of Directors. Dr. Lanckriet brings to Biofrontera more tha |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 3, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF OF BIOFRONTERA INC. Biofrontera Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST. The Amended and Restated Certificate of Incorporation of the Corporation is hereby amended |
|
| July 3, 2023 |
Biofrontera Inc. Announces 1-for-20 Reverse Stock Split Exhibit 99.1 Biofrontera Inc. Announces 1-for-20 Reverse Stock Split WOBURN, Mass. (July 3, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 that will become effectiv |
|
| June 20, 2023 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 2, 2023 |
Letter from Grant Thornton LLP, dated June 2, 2023, to the Securities and Exchange Commission Exhibit 16.1 |
|
| June 1, 2023 |
Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz®-PDT Exhibit 99.1 Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz®-PDT WOBURN, Mass. (June 1, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces it has engaged a contract manufacturer to develop a new, low-cost portable photodynamic |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2023 Biofrontera Inc. (Exact name of registrant as specified in its charter) Delaware 001-40943 47-3765675 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 30, 2023 |
Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer Exhibit 99.1 Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive Officer WOBURN, Mass. (May 30, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces that its Board of Directors has named Hermann Luebbert as Chief Executive Officer. Mr. Lue |
